

To the attention of Henning Gädeke, Chair of the Global Health EDCTP3 Joint Undertaking Governing Board

c/o Michael Makanga, Global Health EDCTP3 Joint Undertaking Executive Director

Global Health EDCTP3 Joint Undertaking

56 - 60 Avenue de la Toison d'Or

1060 Brussels

Belgium

Madrid, 11 March 2026

Letter of endorsement

Dear Sir,

On behalf of LABORATORIOS LICONSA, S.A. ("Liconsa"), PIC 990555950, with registered address at C/ Manuel Pombo Angulo 28, 28050 Madrid, Spain, and pursuant to Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe, I hereby submit this letter of endorsement in support of our role as a contributing partner to the Global Health EDCTP3 Joint Undertaking ("Global Health EDCTP3 JU").

Laboratorios Liconsa, S.A. is a Spanish pharmaceutical company within Chemo, Insud Pharma Group. Founded in 1977, Liconsa has more than 45 years of experience in the pharmaceutical industry. Chemo is a sector leader in the research, development and manufacturing of a broad variety of active pharmaceutical ingredients (APIs) and a full range of Finished Dosage Forms (FDFs) for both human and veterinary use in the main treatment areas. Our group's mission is to improve people's health and well-being by promoting access to affordable, high-quality medicines, while continuing to expand its efforts and investment in R&D to develop new and better therapeutic solutions. These are fully aligned with the objectives of Global Health EDCTP3 JU, where its mission is to reduce mortality and morbidity in sub-Saharan Africa by supporting global collaborative research, capacity strengthening, and speeding up the development, evaluation, and implementation of innovative solutions to prevent, detect, treat and monitor infectious diseases. In this regard, Laboratorios Liconsa, S.A. supports these objectives by developing, manufacturing, leveraging its regulatory expertise to facilitate product approvability and its GMP-compliant industrial capabilities to ensure the availability of new therapeutic tools contribution to the missions outlined above, manufacture and continuous supply of high-quality medicines in accordance with FDA and EMA standards.

Our contribution to Global Health EDCTP3 JU is delivered through our participation in the EDCTP3-funded action Project 101103089 – STOP2030 (*“STOP 2030: Towards the Interruption of Transmission of Soil-Transmitted Helminths: Promoting Implementation of Research Results of a Fixed-Dose Combination of Co-formulated Ivermectin and Albendazole”*), implemented from 1 July 2023 to 30 June 2026, with a project amendment currently under approval that would extend the implementation period until June 2027. The project aims to evaluate and secure the availability of a new, affordable fixed-dose anthelmintic combination of co-formulated albendazole (ALB) and ivermectin (IVM), designed to improve the safety and effectiveness of treatment regimens against soil-transmitted helminths (STH) in pediatric populations in endemic countries. The project aligns with the WHO NTD Roadmap 2021–2030 by accelerating programmatic action, strengthening cross-cutting integration across diseases (with potential applicability beyond STH, such as scabies), and promoting country ownership, including support for registration submissions to national regulatory authorities in the participating Sub-Saharan African countries.

The core clinical component of STOP2030 is a pragmatic safety and effectiveness trial conducted in collaboration with the Ghana Health Service (GHS) and the Kenya Medical Research Institute (KEMRI), with genomic epidemiology support from the Wellcome Sanger Institute. Laboratorios Liconsa, S.A contributes to the clinical trial by acting as its sponsor and, in that capacity, coordinating and implementing—together with the project partners—all required activities. In addition, Laboratorios Liconsa, S.A is responsible for manufacturing the fixed-dose combination (FDC) in accordance with high quality standards.

Furthermore, Laboratorios Liconsa leads Work Package 1, establishing a robust project management structure to ensure efficient operational delivery and liaison with EDCTP3, provide strategic direction, enable effective consortium integration and communication, and ensure high-quality execution within the agreed timelines and budget.

We estimate the total value of this contribution to be EUR 1.267.453,50

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programs, and particularly the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorized by Global Health EDCTP3 JU. Internal dissemination of information within our organization will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our

understanding that Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.

4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

Firmado por ***6897** CARLOS ALBERTO
SECO DE HERRERA (R: ****7613*) el día
06/04/2026 con un certificado emitido
por AC CAMERFIRMA FOR NATURAL PERSONS
- 2016

Madrid, 06 April 2026

Carlos Seco

Pricing & Capital Grants Director

Laboratorios Liconsa S.A.